financetom
Business
financetom
/
Business
/
Robinhood's chief legal officer Gallagher rules out becoming SEC chair, CNBC reports
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Robinhood's chief legal officer Gallagher rules out becoming SEC chair, CNBC reports
Nov 22, 2024 9:18 AM

Nov 22 (Reuters) - Robinhood Markets' ( HOOD ) Chief

Legal Officer Dan Gallagher, a former commissioner of the

Securities and Exchange Commission who was reportedly the

frontrunner to become its chair under Donald Trump, told CNBC on

Friday he was not interested in the role.

"I've made it clear to the relevant people that I'm not

interested in being considered for the role," he said.

Gallagher, a Republican SEC commissioner from 2011 to 2015,

joined Robinhood in 2020. He is expected to play a crucial role

in the retail brokerage's defense in its dispute with the SEC

over potential enforcement action related to the

cryptocurrencies listed on its platform.

His appointment as the SEC chair would have marked a major

milestone for the crypto industry, which has faced stringent

scrutiny under current Chair Gary Gensler.

Gallagher's decision to bow out opens the door for other

contenders. Among them is Paul Atkins, another former Republican

SEC commissioner and CEO of consultancy Patomak Global Partners,

Reuters reported earlier this month.

Robert Stebbins, a partner at law firm Willkie Farr &

Gallagher who served as SEC general counsel during Trump's first

administration, is also in the mix.

Trump's administration is taking shape as he nears his

inauguration in January. On Thursday, the President-elect

appointed Pam Bondi to be U.S. Attorney General.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Paladin Energy Completes A$300 Million Equity Raising to Advance Patterson Lake South Project
Paladin Energy Completes A$300 Million Equity Raising to Advance Patterson Lake South Project
Sep 16, 2025
08:57 AM EDT, 09/16/2025 (MT Newswires) -- Paladin Energy ( PALAF ) said Tuesday that it completed a fully underwritten equity raising for A$300 million in proceeds. The financing comprised an A$231 million institutional placement of new Paladin fully paid ordinary shares on the Australian Securities Exchange, an A$33 million bought deal private placement, and a fully underwritten sale of...
YY Group, UnoMove Sign MoU on Development of Facade Cleaning Drone
YY Group, UnoMove Sign MoU on Development of Facade Cleaning Drone
Sep 16, 2025
08:58 AM EDT, 09/16/2025 (MT Newswires) -- YY Group Holding ( YYGH ) said Tuesday it signed a non-binding memorandum of understanding with autonomous robotics firm UnoMove for the development and future commercialization of UnoMove's facade cleaning drone. The partnership aims to employ autonomous drone technology to significantly lower risks to human workers while enhancing efficiency through technology-driven cleaning methods,...
Update: Trump Files $15 Billion Lawsuit Against New York Times
Update: Trump Files $15 Billion Lawsuit Against New York Times
Sep 16, 2025
08:58 AM EDT, 09/16/2025 (MT Newswires) -- (Updates with New York Times' ( NYT ) response in fourth paragraph) US President Donald Trump said Monday he filed a $15 billion defamation and libel lawsuit against The New York Times ( NYT ) , alleging that the news organization is a mouthpiece for the Democratic Party. Trump accused the New York...
Adial Pharmaceuticals Receives FDA Feedback on AD04 Phase 3 Trial Design for Alcohol Use Disorder
Adial Pharmaceuticals Receives FDA Feedback on AD04 Phase 3 Trial Design for Alcohol Use Disorder
Sep 16, 2025
08:59 AM EDT, 09/16/2025 (MT Newswires) -- Adial Pharmaceuticals ( ADIL ) said Tuesday it received final meeting minutes from its end-of-phase 2 meeting with the US Food and Drug Administration, confirming regulatory alignment on the design of a phase 3 trial for AD04 in alcohol use disorder. Adial said it is implementing FDA recommendations consistent with meeting outcomes to...
Copyright 2023-2026 - www.financetom.com All Rights Reserved